Public Release: 26-Mar-2015
“The drop in carriage seen in this study was faster and more persistent than that seen after vaccination. The harmless bacterial strain was also active against more varieties of N. meningitidis. “
Study suggests possible new approach to prevent spread of disease-causing bacteria
Infectious Diseases Society of America
Nasal drops of harmless bacteria can inhibit a related bug that sometimes causes meningococcal disease, according to new findings published online in Clinical Infectious Diseases. The study–conducted among college students, a group at higher risk for this often serious illness–suggests a new approach that could help suppress outbreaks of the disease, if supported by future research.
Meningococcal disease is caused by Neisseria meningitidis, which can infect the lining of the brain and the spinal cord, causing meningitis. Strains of the bacteria can also cause serious bloodstream infections. But N. meningitidis can also live silently in a person’s nose and throat, without illness. These “colonized” carriers can spread the pathogen to others through close contact.
In the study, researchers placed drops containing low doses of Neisseria lactamica, a related but harmless bacterial strain, into the noses of 149 healthy university students in the United Kingdom. A control group of 161 students received drops of saline instead. Nose swabs were taken at regular intervals over six months and tested for both types of bacteria.
Among students who received the N. lactamica drops and became colonized, the harmless bacteria appeared to prevent N. meningitidis from colonizing the students’ throats. The “good” bacteria also displaced the worrisome pathogen in those who were already carrying it when the study began. The effect was seen after just two weeks, when the number of students carrying N. meningitidis in their upper airway dropped by 9.5 percent among those who were also colonized by N. lactamica using the drops. The effect lasted for at least four months.
“It’s the first time that anyone has taken a bug–a friendly bacterium–and has shown that it changes the way that you can become colonized by the meningitis bacterium, Neisseria meningitidis,” said study author Robert C. Read, MD, of the University of Southampton in the United Kingdom, who described the study as a “proof of principle” with intriguing implications.
Meningococcal vaccines induce high levels of antibodies in the blood to ward off infection, but current vaccines also limit “carriage” of N. meningitidis in the throat, preventing its spread from one person to another. The drop in carriage seen in this study was faster and more persistent than that seen after vaccination. The harmless bacterial strain was also active against more varieties of N. meningitidis.
The findings suggest that N. lactamica may one day help suppress meningococcal outbreaks as a bacterial medicine. Before then, Dr. Read noted, more research is needed, including to confirm that N. lactamica is entirely harmless in a wide population and that it does not change genetically while living in the airway. Determining how to improve carriages rates of N. lactamica also will be necessary before the approach can advance, Dr. Read said.
- Meningococcal disease is caused by Neisseria meningitidis, bacteria that can infect the lining of the brain and spinal cord, causing meningitis. It can also cause serious bloodstream infections.
- The study findings suggest a possible new approach for preventing outbreaks of the disease using a related but harmless type of bacteria, Neisseria lactamica, to displace the disease-causing pathogen in the upper airway.
- More research is needed to support the findings and refine the approach before it can be used in a real world setting to prevent disease.
Editor’s note: The study authors’ affiliations, acknowledgments, and disclosures of financial support and potential conflicts of interests are available in the article. The article is embargoed until 12:01 a.m. EDT on Thursday, March 26. This pre-publication link is for media access only:
Nasal Inoculation of the Commensal Neisseria lactamica Inhibits Carriage of Neisseria meningitidis by Young Adults: A Controlled Human Infection Study
Clinical Infectious Diseases is a leading journal in the field of infectious disease with a broad international readership. The journal publishes articles on a variety of subjects of interest to practitioners and researchers. Topics range from clinical descriptions of infections, public health, microbiology, and immunology to the prevention of infection, the evaluation of current and novel treatments, and the promotion of optimal practices for diagnosis and treatment. The journal publishes original research, editorial commentaries, review articles, and practice guidelines and is among the most highly cited journals in the field of infectious diseases. Clinical Infectious Diseases is an official publication of the Infectious Diseases Society of America (IDSA). Based in Arlington, Va., IDSA is a professional society representing nearly 10,000 physicians and scientists who specialize in infectious diseases. For more information, visit http://www.idsociety.org. Follow IDSA on Facebook and Twitter.